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1. Introduction 
1.1 The concept of lethal reperfusion injury 
Following acute myocardial infarction (AMI), early reperfusion therapy with thrombolytic 
therapy or primary percutaneous coronary intervention therapy (PCI) is the best way to 
salvage the heart by limiting the infarct size and preserving the left ventricular function. The 
early survival benefits of reperfusion are probably sustained lifelong and after 20 years, the 
survival rate of 27% in patients treated with conventional therapy is increased to 37% in 
patients treated with reperfusion therapy (thrombolytics and/or PCI)  (van Domburg et al. 
2005). 
However, the benefits of reperfusion come at a price as restoration of the blood flow in the 
coronary arteries can paradoxically cause myocardial injury. Lethal reperfusion injury 
manifests itself clinically as stunned myocardium, arrhythmias and endothelial damage 
(Yellon and Hausenloy 2007). Although still unclear, the mechanisms behind reperfusion 
injury involve multiple processes including an increase in oxidative stress (Bolli et al. 1989), 
inflammatory damage (Vinten-Johansen 2004), a change in myocyte osmolarity (Garcia-
Dorado and Oliveras 1993), calcium loading (Dong et al. 2006, Murphy et al. 1987) and a 
change in pH (figure 1) (Inserte et al. 2011).  
The rapid return of blood in the ischemic myocardium generates an oxidative stress which 
itself can mediate myocardial injury (Zweier 1988). The release of reactive oxygen species 
consecutive to the oxidative stress may generate a degree of myocardial injury superior to 
ischemia alone, partly due to the reduced bioavailability of the potent vasodilator nitric 
oxide in the vasculature (Zweier and Talukder 2006). The oxidative stress also contributes to 
the excessive increase of intracellular calcium inducing cardiomyocyte death by 
hypercontracture and inadequate opening of the mitochondrial permeability transition pore 
(mPTP) opening (Piper et al. 1998).  The opening of this pore leads to uncoupled oxidative 
phosphorylation , depletion of adenosine triphosphate (ATP) and death (Hausenloy and 
Yellon 2003). Myocardial ischemia causes a progressive decrease in intra- and extra-cellular 
pH (Inserte et al. 2011). At the onset of reperfusion, the removal of extracellular protons and 
the correction of intracellular acidosis exerts an adverse effect due, in part, to the 
intracellular sodium and calcium overload (Piper et al. 1996). An upregulation of cell 
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adhesion molecules during the first hours of reperfusion leads to the accumulation of 
neutrophils in the infarcted area, causing vascular plugging and the release of more reactive 
oxygen species (Vinten-Johansen 2004).  
According to animal studies, lethal reperfusion injury may represent between 20% and 70% 
of the total amount of the irreversible myocardial damage, therefore constituting a major 
therapeutic target. In this regard, the experimental discovery of ischemic pre- and 
postconditioning (Zhao et al. 2003) represents a promising therapy to limit lethal reperfusion 
injury. 
 
Fig. 1. The concept of lethal reperfusion injury 
At the onset of reperfusion, an oxidative stress, a rapid increase in pH, an excess of intra- 
and extracellular calcium and an inflammatory process facilitate the opening of the 
mitochondrial permeability transition pore, leading to lethal reperfusion injury. 
2. Ischemic preconditioning  
2.1 Genesis of an intrinsic cardioprotective solution 
In 1986, Murry et al. published a seminal paper describing a phenomenon whereby four 
cycles of five minutes of coronary artery occlusions with intermittent reperfusion prior to a 
prolonged 40 minutes occlusion, attenuated infarct size to 25% in the canine myocardium  
(Reimer et al. 1986).  Initially, they found that brief periods of ischemia reduced the rate of 
ATP depletion during subsequent ischemic episodes.  Intermittent reperfusion also served 
to prevent the cumulative effects of ischemic injury by washing out potentially harmful 
catabolites such as lactate, hydrogen ions (H+) and ammonia (NH4).  The reduction in ATP 
depletion was associated with the limitation in infarct size.  Given these findings and that 
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the procedure could be reproduced successfully, this cardioprotective phenomenon was 
termed ‘ischemic preconditioning’ (IPC)  (Murry et al. 1986).   
This model of cardioprotection is referred to as ‘classic’ or early preconditioning and is 
short-lived, with the preconditioned state lasting for only 1-4 hours (figure 2)  (Murry et al. 
1991).  However, within 24 hours of the preconditioning stimulus, a late phase of protection, 
known as delayed preconditioning or the second window of protection, is evident but is less 
robust and more prolonged, lasting up to 72 hours after the preconditioning stimulus  
(Baxter et al. 1997). Classic IPC exerts its protective effects via the modification of existing 
proteins. In contrast, delayed preconditioning allows for the de novo synthesis of 
cytoprotective proteins  (Bolli et al. 2007). Another distinction between the two phases is that 
although classic IPC limits infarct size, it does not protect against postischemic myocardial 
contractile dysfunction or stunning. Conversely, late IPC reduces myocardial cell death and 
preserves left ventricular function  (Bolli et al. 2007). These disparities suggest that late IPC 
would provide greater clinical benefits in terms of greater and longer lasting protection. 
 
Fig. 2. Schematic representation of classic and delayed postconditioning 
2.2 Remote preconditioning 
Further research into the development of IPC yielded the discovery that remote ischemia 
distant to the heart can elicit a similar cardioprotective response as IPC of the local coronary 
artery. Four brief occlusions of the circumflex branches lasting 5 minutes and interspersed 
by 5 minutes of reperfusion had a remote infarct reducing effect on the ischemic canine 
myocardium supplied by the left anterior descending artery  (Przyklenk et al. 1993). This 
protective effect was termed remote preconditioning. Subsequent studies have shown that 
ischemic bursts could be successfully applied to organs such as the intestine  (Gho et al. 
1996), skeletal muscle  (Addison et al. 2003) and kidney  (Pell et al. 1998) and as a result, 
precondition the myocardium. 
2.3 Clinical relevance 
Although preconditioning is not applicable for patients with AMI, it may serve to alleviate 
the high risk of myocardial infarction in patients with unstable angina. Furthermore, 
preconditioning strategies can be applied prior to coronary artery bypass graft (CABG) 
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surgery to prevent a potentially injurious ischemia insult. A proof-of concept study supporting 
remote preconditioning of the upper limb in adult patients prior to elective CABG showed 
significantly reduced serum troponin-T levels  (Hausenloy et al. 2007). The cardiac remote 
ischemic preconditioning (CRISP) study implemented remote preconditioning (induced by 
three 5-minute inflations of a blood pressure to 200 mmHg in the upper arm and followed 
by three 5-minute reperfusion intervals) before elective PCI in a randomized control trial  
(Hoole et al. 2009). Subject who received the remote IPC had reduced cardiac troponin I 
release, suffered from less chest pain and ECG ST-segment deviation. In addition, there was 
a reported improvement in the major adverse cardiac and cerebral event (MACCE) rate. The 
beneficial use of remote IPC has also been successfully translated to children with congential 
defects undergoing a cardiopulmonary bypass  (Cheung et al. 2006).  
3. Ischemic postconditioning: A promising therapy to limit reperfusion injury 
Discovered in 2003, ischemic postconditioning, achieved by repetitive brief bouts of 
ischemia at the onset of reperfusion, protects against reperfusion injury and offers a clinical 
approach in patients with AMI (Zhao et al. 2003). Three episodes of 30 secs of reperfusion 
and 30 secs of ischemia, performed at the onset of reperfusion following a 60 min ischemic 
insult in dog hearts, protected against reperfusion injury (Zhao et al. 2003). Its infarct 
limiting effect is comparable to ischemic preconditioning and can reduce the infarct size by 
up to 80% (figure 3)  (Zhao et al. 2003). Postconditioning has been successful in multiple 
animal species such as canines, rats, mice and rabbits (Zhao and Vinten-Johansen 2006). 
Ischemic pre- and postconditioning, used in combination, did not produce any significant 
benefit over the strategies used separately, which may suggest the activation of similar 
protective mechanisms by both phenomena (Halkos et al. 2004). 
 
Fig. 3. Ischemic postconditioning decrease infarct size 
In animal models subjected to an ischemia-reperfusion insult, ischemic postconditioning 
performed by short cycles of ischemia-reperfusion at the onset of reperfusion, dramatically 
reduces the infarct size (dead cells in white). 
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3.1 Ischemic postconditioning: A rapid translation from bench to bedside 
Considering that postconditioning was only discovered in 2003, (Zhao et al. 2003) it is 
remarkable how quickly it made the leap to proof-of-concept clinical trials (figure 4). In 
2005, Staat et al published a landmark study whereby postconditioning, applied during the 
first minutes of reperfusion to AMI patients undergoing emergency PCI, reduced 
myocardial damage measured through creatine kinase release over 72 hours (Staat et al. 
2005). After reperfusion by direct stenting, postconditioning simply performed within the 
first minute of reperfusion by 4 cycles of 1 min inflation/deflation of the angioplasty 
balloon, reduced the infarct size by 36%. Using more specific endpoints, the same group 
later confirmed that their postconditioning protocol was associated with a reduction of the 
infarct size (measured by 201thallium single photon emission computed tomography 
technique after 6 months) and improved myocardial contractile function (measured by 
echocardiography) after 1 year  (Thibault et al. 2008).  At 1 year, their pilot study, performed 
on 38 patients only, showed a 7% increase in the left ventricular ejection fraction in the 
postconditioned patients (Thibault et al. 2008).  Animal studies have shown that optimizing 
the postconditioning protocol is an important process for the success of the therapy (van 
Vuuren and Lochner 2008). Few human studies seem to confirm this statement. 
Postconditioning the human heart with three cycles of 30 sec inflation and 30 sec deflation of 
the angioplasty balloon, within the first 3 min of reperfusion, reduced the infarct size by 
27% (Yang et al. 2007). In a retrospective analysis of patients undergoing primary 
angioplasty, the release of creatine kinase in patients who received 4 or more balloon 
inflations was lower than in patients who received between 1 and 3 balloon inflations 
(Darling et al. 2007).  
When measuring the area at risk before reperfusion in patients undergoing primary PCI, the 
benefit of ischemic postconditioning performed with 4 cycles of 60s reperfusion and 60s 
reocclusion is not observed in the overall population with ST elevation myocardial 
infarction but seems to be of value for patients with large areas at risk. Hence, the regression 
analysis in which the final infarct size was related to the myocardial area at risk showed a 
significant difference between the control and postconditioning groups  (Sorensson et al.). 
With regards to long term benefit of ischemic postconditioning, a study of 43 patients 
suggested that the protective effect on cardiac function tends to persist beyond 3 years, but 
larger studies are needed to confirm its long term effect (Garcia et al. 2010). 
The benefit of postconditioning can be extended to cardiac surgery. In patients undergoing a 
valve replacement under cold blood cardioplegic arrest, postconditioning (performed by 3 
cycles of 30 sec ischemia and 30 sec reperfusion using aortic clamping) reduced the creatine 
kinase release, transcardiac neutrophil count and the use of inotropic agents during 
reperfusion (Luo et al. 2008).  
Remote postconditioning, whereby the postconditioning protocol applied in one part of the 
body results in protection of a remote region undergoing ischemia-reperfusion, is successful 
in animal models (Andreka et al. 2007) and may represent a more practical way to protect 
the human heart than ischemic postconditioning. Recently, remote perconditioning was 
tested in Danish patients on their way to hospital to receive primary PCI (Botker et al.). 
Remote perconditioning was performed by 4 cycles of 5min inflation/deflation of the blood 
pressure cuff on the arm of 251 patients. 30 days after reperfusion, the myocardial salvage 
measured by SPECT imaging was increased by remote perconditioning. 
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Fig. 4. The concept of conditioning the heart and its clinical applications 
3.2 Mechanisms involved in ischemic postconditioning: RISK and SAFE pathways 
Following the discovery of ischemic preconditioning in 1986 (Murry et al. 1986), intensive 
research was performed to elucidate the intrinsic prosurvival cascades that can be activated 
within the heart to limit reperfusion injuries. The delineation of the reperfusion injury 
salvage kinase (RISK) pathway proved to be a very powerful survival pathway to limit cell 
death at the onset of reperfusion. More recently, the delineation of another prosurvival 
signaling cascade termed as the survivor activating factor enhancement (SAFE) pathway 
and involving the activation of the immune system, offers new potential to limit further 
reperfusion injury. 
3.2.1 RISK pathway 
The actual term reperfusion injury salvage kinase (RISK) pathway was first coined in 2002, 
in a study investigating the signal transduction pathway underlying the infarct-limiting 
effects of urocortin administered at reperfusion (Schulman et al. 2002). Activation of this 
pathway involves two prosurvival kinases pathways: phosphatidylinositol-3 kinase 
(PI3K)/Akt and mitogen extraregulated kinase 1/2 (MEK1/2)-extraregulated kinase 1/2 
(Erk1/2). Activation of both Erk1/2 and Akt at the onset of reperfusion is generally 
associated with a reduction of the infarct size and their inhibition with pharmacological 
agents is often associated with a loss of the infarct sparing effect of many cardioprotective 
drugs (Hausenloy et al. 2011).  
In ischemic postconditioning, the RISK pathway is activated at the onset of reperfusion  by 
cell surface receptors including G-protein coupled receptors, cytokine receptors, tyrosine 
kinase receptors and serine/threonine receptors (Hausenloy and Yellon 2009). Adenosine 
receptors (Morrison et al. 2007) and sphingosine kinase-1 receptors (Jin et al. 2008) activate 
the RISK pathway and it is probable that many other cell-surface implicated as triggers in 
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ischemic postconditoning, such as bradykinin and opioids receptors, also activate the RISK 
pathway but this remains to be demonstrated directly. 
Activation of Akt and Erk1/2 leads to the activation of endothelial nitric oxide synthase 
(eNOS) and P70S6Kinase (Tsang et al. 2004). There are several other protein kinases that 
have been implicated in ischemic postconditioning signaling which could also be considered 
as components of the RISK pathway such as protein kinase C (PKC), protein kinase G, p38 
mitogen-activated protein kinase (p38MAPK) and Jun N-terminal kinase MAPK.  
3.2.2 mPTP and anti-apoptotic signaling pathways activated by the RISK pathway 
There are a number of downstream effectors of the RISK pathway which could be 
responsible for the cardioprotection elicited by ischemic postconditioning. Many of these 
terminate on the mitochondria an organelle which occupies an essential role in 
cardiomyocyte survival and death signaling.   
The opening of the mitochondrial permeability transition pore (mPTP) at the onset of 
myocardial reperfusion is a critical determinant of lethal myocardial reperfusion injury, 
such that pharmacologically inhibiting its opening at this time can reduce myocardial infarct 
size by 40-50% in both the laboratory (Argaud et al. 2005, Hausenloy et al. 2002) and clinical 
setting (Bolli et al. 2004). Although the actual identity of the pore-forming units of the mPTP 
is unknown, several studies have demonstrated mitochondrial cyclophilin-D (CypD) to be a 
major regulatory component of the mPTP, such that mice lacking CypD appear resistant to 
mPTP opening and sustain greatly reduced myocardial infarct sizes (Baines et al. 2005, 
Nakagawa et al. 2005). The actual mechanism through which the Akt and Erk1/2 
components of the RISK pathway mediate mPTP inhibition is unclear, although potential 
explanations include: (1) the generation of nitric oxide by endothelial nitric oxide synthase 
(eNOS), a downstream target of the RISK pathway can inhibit mPTP opening (Kim et al. 
2004); (2) Akt may modulate mitochondrial morphology thereby rendering mitochondria 
more resistant to mPTP opening (Ong et al. 2010);  (3) Akt may modulate intracellular 
calcium handling- by increasing sarcoplasmic reticulum calcium uptake it may prevent 
mPTP opening (Abdallah et al. 2006); (4) Glycogen synthase kinase (GSK3ǃ), a downstream 
target of both Akt and extracellular regulated kinase (Erk) 1/2 may act as a point of 
convergence for a variety of pro-survival signaling pathways resulting in mPTP inhibition 
(Juhaszova et al. 2004, Juhaszova et al. 2009). 
The possibility of recruiting anti-apoptotic signaling pathways had been one of the original 
reasons for proposing the RISK pathway as a pro-survival signaling pathway, particularly 
given the close association of apoptotic cell death with the reperfusion phase (Yellon and 
Baxter 1999). Interestingly, although a large number of potential anti-apoptotic pathways 
exist downstream of the RISK pathway, relatively few have actually been investigated in the 
context of cardioprotection, yet alone ischemic postconditioning. These anti-apoptotic 
mechanisms include: the phosphorylation and inhibition of pro-apoptotic proteins such as 
BAD (Bcl-2 antagonist of cell death)  (Jonassen et al. 2001), BAX (Bcl-2-associated X protein) 
and the activation of anti-apoptotic proteins such as PIM-1 kinase (Hausenloy and Yellon 
2009), the effect of which is preservation of mitochondrial integrity and a favorable increase 
in the anti-apoptotic proteins such as BCL2 (B-cell lymphoma-2) and BCL-XL (B-cell 
lymphoma-xl).  
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Fig. 5. Prosurvival pathways activated by postconditioning 
Ischemic postconditioning activates two powerful prosurvival pathways termed as the 
SAFE and RISK paths. Both pathways reduce lethal reperfusion injury by limiting the 
opening of the mitochondrial permeability transition pore (mPTP). SAFE, Survivor 
Activation Factor Enhancement; TNFǂ, Tumour Necrosis Factor alpha; JAK, Janus Kinase; 
STAT-3, Signal Transducer and Activator of Transcription-3, RISK, Reperfusion Injury 
Salvage Kinase; PI3K, Phosphoinositol 3-Kinase; MEK, Mitogen activated protein kinase 
Extracellular regulated Kinase; ERK, Extracellular Regulated Kinase. 
3.2.3 SAFE pathway 
In animal studies, the involvement of the RISK pathway has sparked few inconsistencies, 
supporting the existence of an alternative prosurvival signal transduction pathway for 
protecting the ischemic myocardium against lethal reperfusion injury (Lecour 2009b). In this 
respect, our laboratory has recently described a novel pro-survival pathway, which involves 
the activation of tumor necrosis factor alpha (TNF) and the transcription factor, signal 
transducer and activator of transcription 3 (STAT-3), that we have termed as the Survivor 
Activating Factor Enhancement (SAFE) pathway (figure 5)  (Lecour 2009a, b). The SAFE 
pathway was first discovered in the setting of ischemic preconditioning and its role in 
ischemic postconditioning has only been recently confirmed.  
TNF, a proinflammatory cytokine expressed in all nucleated cell types including 
cardiomyocytes, exerts its major effects after binding onto its cell surface receptors TNF 
receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). The two TFNRs differ in their signal 
pathways with TNFR1 activating both apoptotic and protective signaling whereas TNFR2, 
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although poorly studied, seem to convey prosurvival signaling only (Schulz and Heusch 
2009). In a dose and time-dependent manner and function to which type of receptor is 
activated, TNF can be either protective or deleterious. There are now a large number of 
experimental data supporting the evidence that ischemic postconditionng requires 
activation of low concentrations of TNF to confer cardioprotection via TNFR2 (Lecour 
2009b). Activation of the receptors phosphorylates the janus kinase (JAK) protein, which in 
turn, can activate the transcription factor STAT-3. In 2006, the role of STAT-3 in ischemic 
postconditioning was also suggested in an isolated rat heart model whereby the addition of 
the JAK/STAT-3 inhibitor AG490 at the onset of reperfusion abolished the cardioprotective 
effect of ischemic postconditioning (Suleman et al. 2006). Both ischemic and pharmacological 
postconditioning with TNF failed to confer an infarct sparing effect in isolated STAT3-
deficient murine hearts subjected to ischemia-reperfusion injury (Boengler et al. 2008, 
Lacerda et al. 2009). Furthermore, the absence of protection observed in TNF or TNFR2 
knockout mice was associated with the absence of STAT-3 phosphorylation (Lacerda et al. 
2009). Activation of TNF/TNR2/JAK/STAT-3 may be triggered by various mediators 
including insulin, angiotensin II, bradykinin, adrenoreceptors, opioids, cannabinoids and 
sphingosine-1 phosphate (Hausenloy et al. 2011). 
3.2.4 mPTP and anti-apoptotic signaling pathways activated by the SAFE pathway 
 TNF-induced protection requires the activation of protein kinase C, the mitochondrial ATP-
dependent potassium channel and NFκ-B (Lecour et al. 2002, Somers et al. 2005). In addition, 
pharmacological preconditioning with TNF is associated with an increase in mitochondrial 
free radicals and an addition of free radical scavengers such as mercaptopropionyl glycine 
abolished its cardioprotective effect (Lacerda et al. 2006, Lecour et al. 2005a). In contrast, 
neither p38MAPK, Akt, Erk nor GSK3-ǃ seem to be involved in TNF-induced 
cardioprotection, therefore suggesting that they do not act as the downstream target of the 
SAFE pathway (Lacerda et al. 2009, Lecour et al. 2005b, Tanno et al. 2003). STAT3 mediates 
cardioprotection via the phosphorylation and inactivation of the pro-apoptotic factor Bad 
(Deuchar et al. 2007, Lecour et al. 2005b) and Bax (Huffman et al. 2008). The mitochondrial 
permeability transition pore (mPTP) is described as an end-effector of ischemic 
postconditioning and the RISK pathway and there are now strong evidence that the SAFE 
pathway may also target the mPTP. Hence, STAT3 expression was demonstrated in 
mitochondria, playing a role in cell respiration (Wegrzyn et al. 2009) and mPTP opening 
(Boengler et al. 2010).  
3.3 Targeting the RISK and SAFE paths to limit reperfusion injury 
Ischemic postconditioning performed by inflation/deflation of the angioplastic balloon is 
safe, easy to perform, inexpensive but many patients in remote areas do not have a fast 
access to a PCI performing facility and ischemic postconditioning has never been tested 
following thrombolysis. The development of pharmacological drugs which can mimic 
ischemic postconditioning by activating the prosurvival RISK and SAFE pathways would 
benefit patients undergoing either PCI or thrombolysis and it would certainly be more 
practical than ischemic postconditioning. 
In this regards, the immunosuppressor drug cyclosporine can bind to the mitochondrial 
cyclophilin D, thereby inhibiting the opening of the mPTP, a downstream target of both the 
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RISK and SAFE pathways. In a multicenter single-blinded controlled clinical trial, the effect 
of cyclosporine A was evaluated in 58 patients with acute ST-elevation myocardial 
infarction who received an intravenous bolus of 2.5mg/kg of cyclosporine immediately 
before undergoing PCI, significantly reduced the release of creatine kinase by 40% within 
the first 72 hours. (Piot et al. 2008) Infarct size, assessed on day 5 (by measuring the area of 
hyperenhancement on magnetic resonance imaging) was significantly reduced. 
Cyclosporine, routinely used as an immunosuppressive agent, is well known for its toxic 
side-effects, such as renal and hepatic toxicity and increased susceptibility to infections and 
cancers. A single bolus injection of cyclosporine did not show any of these side-effects, but 
larger and longer clinical trials are required to prove the safety and efficacy of cyclosporine 
as a therapeutic agent following AMI. 
Two clinical trials have explored the effect of adenosine in patients with acute myocardial 
infarction (AMISTAD and AMISTAD II) but the results were mitigated by the 
haemodynamic effect of the drug. (Mahaffey et al. 1999, Ross et al. 2005) Although adenosine 
can successfully reduce the infarct size, it has a vasodilatory and negative chronotropic 
effect, causing hypotension and bradycardia, thus limiting its clinical application. However, 
recent experimental studies using polyethylene glycol liposomal adenosine in rats protected 
against ischemia-reperfusion and reduced the hemodynamic effect of adenosine. (Takahama 
et al. 2009) If this protocol can be applied in a clinical setting, it may limit the side effects of 
adenosine.  
Erythropoietin successfully reduced the infarct size in animal models but its clinical 
application still needs to be confirmed. (Bullard et al. 2005)  
3.4 Ischemic postconditioning and comorbidities 
At the present, little information is available in humans with regards to the success of 
ischemic postconditioning with different comorbidities and most of the clinical trials have 
excluded patients with diabetes/metabolic syndrome. Animal studies have shown that 
various comorbidities affect the protective effect of postconditioning. Rats with obesity, 
metabolic syndrome or diabetes become more resistant to the infarct limiting effect of 
ischemic postconditioning and additional cycles of ischemia-reperfusion are required to 
achieve a beneficial effect (Hausenloy et al. 2011). Similarly, hyperglycemia in rabbits 
abolishes the cardioprotective effect of ischemic postconditioning (Raphael et al.). More 
recently, depressed rats failed to be protected with ischemic postconditioning (Zhuo et al. 
2011). 
4. Conclusion 
Ischemic postconditioning is a safe, simple and inexpensive therapy but several factors need 
to be taken into consideration for its efficacy. Remote ischemic postconditioning and 
pharmacological postconditioning present the advantage of being applied in AMI patients 
with or without PCI. However, the severity and duration of ischemia, the presence of collateral 
circulation and the algorithm of the postconditioning protocol may all affect the protective 
effect of ischemic postconditioning against lethal reperfusion injury (Hausenloy et al. 2010).     
Although small clinical proof-of-concept studies suggest that ischemic postconditioning can 
protect the human heart against lethal reperfusion injuries, larger clinical trials testing 
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ischemic or pharmacological postconditioning are needed to test the clinical outcome of this 
phenomenon. In Italy, the POSTAMI trial is currently evaluating the effect of ischemic 
postconditioning on infarct size (using magnetic resonance imaging) 3 months after ST 
elevation AMI in 78 patients (Tarantini et al. 2010). In Norway, the POSTEMI study is 
currently evaluating the effect of ischemic postconditioning on infarct size after 4 months by 
magnetic resonance imaging in 260 patients (Limalanathan et al.). Most importantly, the 
CIRCUS study aims to evaluate whether cyclosporine A, given immediately prior to 
reperfusion with PCI, can improve clinical outcome in patients with AMI. Conducted in 15 
countries and 120 centres, the study will evaluate 1750 patients per group considering cardiac 
death and hospitalization for in-hospital worsening of heart failure as primary endpoints. The 
outcome of these larger clinical trials will hopefully conclude that postconditioning should be 
systematically applied in the management of future patients with AMI. 
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